Thursday, December 14, 2017 10:15 PM ET
Insider Sale at Intellia Therapeutics (NTLA) Continues Selling Trend
There was a notable insider sale of Intellia Therapeutics shares today, as revealed in a filing with the SEC as — Novartis Institutes for BioMedical Research Inc, 10% Owner — disposed of 1,523,000 shares in the company having a market value of approximately $27,870,900 There was one insider buy/sell transaction in the past 90 days prior to this transaction which resulted in the sale of 336,783 shares. Adding the most recent activity to this 90-day history indicates insider trades have been net sales of 1,859,783 shares and have averaged 929,892 shares per transaction over this time period.
In relation to the peer group over the last 90 days, insider buy/sell trading at Intellia Therapeutics is above the 188-company peer group average. Biotechnology & Medical Research peer group saw 168 buy/sell trades during this period for an average of 0.9 transactions per company. The number of shares per buy/sell trade for Intellia Therapeutics insiders was also higher. Within the peer group there were 27,158,124 shares purchased and 23,949,949 shares sold with company insiders purchasing 26,735 shares on average.
To bring into focus significant insider buying and selling activity, all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers has been eliminated in data obtained to evaluate and write this story.
Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.
For more information, contact UpTick at firstname.lastname@example.org. Copyright 2017 UpTick Data Technologies. All rights reserved.